Abstract
We investigated the characteristics and target cell recognition of CD3·LAK induced by anti-CD3 monoclonal antibody (mAb) and interleukin 2 (IL-2) from peripheral blood lymphocytes (PBL) on the patients with oral squamous cell carcinoma.
‹Materials and Methods› CD3·LAK were induced by 10μg/ml of anti-CD3mAb (solid phase) and 700JRU/ml of IL-2 (S6820). Surface marker of CD3·LAK were detected by flow cytometry. A 4-h51Cr release assay was used to detect cytotoxic activity. Cultured tumor cell lines, which are Ca9-22 (established from squamous cell carcinoma of the lower gingiva: case 1), NA (established from squamous cell carcinoma of the tongue) and K562, were used as target cells. The expression of HLA antigen on the surface of the cultured tumor cell lines were detected by flow cytometry prior to 4-h 51Cr releas eassay detection. In order to investigate the target cell recognition of CD3·LAK, inhibition assay with mAb were done.
‹Results› On day 19, CD3·LAK population mainly consisted of TCR α/β positive T cell (CD3+) and NK cell (CD3-NKH-1+), and remaining portion was TCR γ/δ positive T cell (CD3+). The CD3·LAK showed the cytotoxic activities against autologous and allogeneic cultured tumor cell lines, and these activities were inhibited by anti-CD3 monoclonal antibody. Ho wever the cytotoxic activities against K562 were not inhibited by anti-CD3 monoclonal antibody. These results indicate that the target cell recognition of CD3·LAK does not need MHC-restriction. CD3·LAK maybe concerned with two different types of target cell recognition which can either be through TCR/CD3 complex or none at all.
